J&J Staves Off Generic Topamax

Law360, New York (February 13, 2007, 12:00 AM EST) -- A federal judge has sided with a Johnson & Johnson company in a patent infringement case over Topamax, keeping Mylan Laboratories Inc.’s generic version of the epilepsy drug off the shelf.

Earlier this month, Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey rejected Mylan’s arguments that Ortho-McNeil Pharmaceutical Inc.’s patent was invalid due to obviousness, and granted Ortho-McNeil’s motion for partial summary judgment.

Mylan had contended that Ortho-McNeil’s patent on Topamax covered subject matter considered obvious to an individual...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.